Teva Pharmaceutical Industries (TEV) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Teva/Alvotech follow Amgen in launching biosimilar for J&J’s StelaraFebruary 21 at 8:40 AM | msn.comIs Teva Pharmaceutical (TEVA) Trading at a Discount?February 19 at 10:48 AM | msn.comTeva EVP Mark Sabag sells $2.89 million in sharesFebruary 14, 2025 | msn.comEvercore ISI Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)February 3, 2025 | markets.businessinsider.comTeva Pharmaceutical Industries Ltd (TEVA) Q4 2024 Earnings Call Highlights: Strong Revenue ...January 31, 2025 | finance.yahoo.comBofA cuts TEVA stock price target to $23, maintains Buy ratingJanuary 30, 2025 | msn.comTeva sees FY25 EPS $2.35-$2.65, consensus $2.47January 29, 2025 | markets.businessinsider.comTeva Pharmaceutical shares tumble as 2025 outlook disappointsJanuary 29, 2025 | msn.comTeva Swings to 4Q Loss as Revenue FallsJanuary 29, 2025 | marketwatch.comCorruption investigation opened into Teva following employee's complaintJanuary 29, 2025 | msn.comCorruption investigation opened into Teva following employee's complaintJanuary 29, 2025 | msn.comTeva Pharm Q4 tops estimates on strong sales of its own drugsJanuary 29, 2025 | reuters.comTeva Pharmaceuticals: Promising Growth Prospects and Buy Rating ReaffirmedJanuary 23, 2025 | markets.businessinsider.comTeva price target raised to $30 from $28 at UBSJanuary 23, 2025 | markets.businessinsider.comUBS lifts Teva stock price target to $30, maintains Buy ratingJanuary 23, 2025 | msn.comTeva sues CMS over Medicare drug price negotiationsJanuary 19, 2025 | seekingalpha.comTeva enters pact with Klinge Biopharma, Formycon to commercialize FYB203January 13, 2025 | markets.businessinsider.comTeva inks partnership with Klinge to launch Eylea biosimilar in EuropeJanuary 13, 2025 | msn.comTeva Collaborates With Klinge, Formycon For Semi-exclusive Commercialization Of FYB203January 13, 2025 | markets.businessinsider.comTeva, Samsung Bioepis enter partnership for commercialization of EPYSQLIJanuary 10, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals Jumps 14% on Firdapse Settlement With TevaJanuary 9, 2025 | marketwatch.comCatalyst Pharmaceuticals up 18% after resumption following Teva settlementJanuary 9, 2025 | markets.businessinsider.comWhy Teva Pharmaceuticals Industries Ltd. (TEVA) Crashed YesterdayJanuary 3, 2025 | msn.comPositive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn'sDecember 17, 2024 | msn.comTeva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial ExpectationsDecember 17, 2024 | finance.yahoo.comTeva, Sanofi say bowel disease drug met primary targetsDecember 17, 2024 | msn.comTeva, Sanofi gain after mid-stage trial win for IBD therapyDecember 17, 2024 | msn.comCan Teva Return To All-Time Highs?December 6, 2024 | seekingalpha.comTeva: Becoming Increasingly Solid, But No Longer UndervaluedDecember 5, 2024 | seekingalpha.comTeva presents data from SPACE studyDecember 5, 2024 | markets.businessinsider.comTeva reports positive outcomes from episodic migraine trial in young patientsDecember 5, 2024 | finance.yahoo.comTeva Pharmaceutical Indus Unusual Options ActivityNovember 29, 2024 | benzinga.comTeva Pharmaceutical: Teva Takes on Antimicrobial Resistance: What You Need to KnowNovember 21, 2024 | finanznachrichten.deTeva Pharmaceutical Strengthens Board with New AppointmentNovember 14, 2024 | markets.businessinsider.comTeva Reports Strong Q3 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comTeva sees FY24 EPS $2.40-$2.50, consensus $2.45November 6, 2024 | markets.businessinsider.comGeneric Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual ForecastNovember 6, 2024 | benzinga.comSevere Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightNovember 6, 2024 | finance.yahoo.comTeva gains after raising outlook for second time this yearNovember 6, 2024 | msn.comTeva Pharmaceutical sees more growth in 2025 after strong Q3November 6, 2024 | msn.comTeva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | finance.yahoo.comTeva Pharmaceutical third-quarter profit, revenue top estimatesNovember 6, 2024 | reuters.comTeva presents Phase 3 SOLARIS trial resultsNovember 2, 2024 | markets.businessinsider.comTeva long-acting olanzapine shows improvements in schizophrenia patientsNovember 1, 2024 | msn.comTeva fined $500M by EU for disparaging rival MS drug (update)November 1, 2024 | seekingalpha.comEU Commission Fines Teva $500 Million for Trying to Stop Rival's Multiple Sclerosis DrugOctober 31, 2024 | msn.comTeva Fined Around $500 Million by EU Over MS Drug Competition ConcernsOctober 31, 2024 | wsj.comTeva Hit With €463 Million EU Fine for Talking Down RivalsOctober 31, 2024 | bloomberg.comFDA approves Alvotech and Teva’s SELARSDI for new indicationsOctober 23, 2024 | msn.comTeva Pharmaceutical (TEVA) Receives a Buy from BarclaysOctober 23, 2024 | markets.businessinsider.com Get Teva Pharmaceutical Industries News Delivered to You Automatically Sign up to receive the latest news and ratings for TEV and its competitors with MarketBeat's FREE daily newsletter. Email Address TEV Media Mentions By Week TEV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TEV News Sentiment▼0.000.60▲Average Medical News Sentiment TEV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TEV Articles This Week▼22▲TEV Articles Average Week Get Teva Pharmaceutical Industries News Delivered to You Automatically Sign up to receive the latest news and ratings for TEV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genfit News Merck KGaA News MorphoSys News ad pepper media International News Evotec News Fielmann Group News Fresenius SE & Co. KGaA News Sanofi News Sartorius Stedim Biotech News Siemens Healthineers News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (FRA:TEV) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Teva Pharmaceutical Industries With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
